MTHFD1/2 inhibitor - One-carbon Therapeutics
Latest Information Update: 06 Jan 2023
At a glance
- Originator One-carbon Therapeutics
- Class Antineoplastics
- Mechanism of Action Methylenetetrahydrofolate reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer